水包油包固体乳化法制备蛋白药物缓释微球

以牛血清白蛋白(BSA)为模型药物, 研究了一种新型载药微球的水包油包固体(S/O/W)乳化法. 用纳米尺寸的SiO2吸附溶液中的BSA, 得到粒径约为30 nm的含药粒子, 再用PLGA包裹含药粒子. 考察不同制备条件对载药量和包封率的影响, 并与传统的双乳法(W/O/W)进行了对比, 发现该制备方法提高了药物的载药量(由2.5%到3.1%)和包封率(由72%到90%以上), 同时提高了药物活性.     

壳聚糖─海藻酸钠微囊对蛋白质控制释放的研究

采用乳化法制备了可注射用壳聚糖海藻酸钠微囊, 其粒径小于２００ μｍ ,且具有相对较窄的近似高斯分布。牛血清白蛋白作为模型药物在微囊中的包埋率可超过５０ ％ 。通过壳聚糖在海藻酸钠微囊表面的复合,牛血清白蛋白从微囊中的持续释放时间从几个小时延长到半个月以上。     

BSA载药微囊的制备、表征及体外释放行为

采用复乳法-液中干燥法制备了一系列含有牛血清蛋白(BSA)的聚乙二醇-b-聚(6-(乙酸苄酯)-ε-己内酯-co-ε-己内酯(PEBCL)微囊.分别研究了聚合物结构以及制备条件对微囊粒径、载药量和包封率的影响,同时研究了载药微囊在pH=7.4的磷酸盐缓冲溶液中的体外释放行为.研究表明:微囊的平均粒径13～30 μm,微囊对BSA的载药量和包封率分别最高可以达到14.18%和75.90%,药物的释放行为可控,PEBCL微囊作为蛋白质类药物载体有望在临床上获得应用.     

壳聚糖—海藻酸钠微囊对蛋白质控制释放的研究

采用乳化法制备了可注射用壳聚糖－海藻酸钠微囊，其粒径小于２００μｍ，且具有相对较窄的近似高斯分布。牛血清白蛋白作为模型药物在微囊中的包埋率可超过５０％。通过壳聚糖在海藻酸钠微囊表面的复合，牛血清白蛋白从微囊中的持续释放时间从几个小时延长到半个月以上。     

一种新型季胺盐壳聚糖纳米载药体系的制备与性能

在制备壳聚糖衍生物N,N,N-三甲基壳聚糖盐酸盐(TMC)的基础上,通过将两种性质相反的电解质溶液进行共混,制备了一种新型的 TMC/CMC(羧甲基壳聚糖)纳米载药颗粒体系.用激光散射仪和透射电镜表征了空白颗粒和载药颗粒的粒径、粒径分布、Zeta 电位和形态结构.栽药体系纳米颗粒的粒径在 200～600 nm 范围,表面可带正或负电荷,且 Zeta 电位具有可调性.研究表明:牛血清蛋白(BSA)的包封率与起始的 TMC、BSA 浓度相关;纳米载药颗粒对 BSA 的释放表现为,先爆释而后缓释并可保持 40 h 以上的释放.     

CoFe_2O_4纳米晶与牛血清白蛋白和牛血红蛋白的相互作用:吸附、纳米晶的团聚及蛋白构象的变化(英文)

水热制备了约10 nm的CoFe2O4纳米晶,通过Zeta电势、动态光散射(Dynamic Light Scattering,DLS)和傅立叶变换红外光谱(FTIR)技术研究了纳米晶与牛血清白蛋白(Bovine Serum Albumin,BSA)和牛血红蛋白(Hemoglobin)的相互作用。纳米晶对BSA和血红蛋白都有很强的吸附,其中对血红蛋白的吸附符合静电吸附的规律,而对BSA的吸附则不符合静电吸附的规律。在pH=5.5和7.0时纳米晶对BSA和血红蛋白的吸附容量分别达到237.9 mg·g-1和256.9 mg·g-1。DLS结果表明蛋白质能够导致纳米晶团聚。吸附BSA或血红蛋白后,纳米晶的DLS粒径由51 nm分别增大到472 nm和114 nm。CoFe2O4纳米晶还导致了蛋白质FTIR谱发生明显变化。BSA和血红蛋白的酰胺I带由于纳米晶的作用分别减少了4 cm-1和6 cm-1。     

白藜芦醇白蛋白纳米粒的制备及其抗卵巢癌细胞增殖作用的研究

以牛血清白蛋白(BSA)为载体, 用去溶剂化-化学交联法制备白藜芦醇白蛋白纳米粒(RES-BSANP). 以原子力学显微镜(AFM)观察其形态, 用高效液相色谱法(HPLC)对制备的纳米微粒进行分析. 采用四甲基偶氮唑盐微量酶反应比色法(MTT)及流式细胞技术(FCM)比较RES-BSANP和RES对卵巢癌SKOV3细胞的抗增殖活性及对细胞周期和凋亡的影响. 结果表明, 获得的RES-BSANP纳米粒的平均粒径为400～500 nm, 表面光滑, 12 mg纳米粒中RES载药量为4.077 mg, 包封率33.97％, 24 h内的稳定性好, 水溶性较RES显著提高. 二者的抗肿瘤增殖作用呈剂量依赖性, 中高浓度组纳米粒组的抗增殖活性及凋亡细胞比率显著提高. 两种药物均使细胞周期阻滞于G0/G1+S期, 纳米组使进入S期细胞比率明显增加, 表明白藜芦醇白蛋白纳米粒在抗卵巢癌细胞增殖方面有广阔的应用前景.     

适配子修饰靶向PLGA纳米基因载体的构建

化学合成了功能性三嵌段复合物乳酸乙醇酸共聚物-聚乙二醇-适配子(PLGA-PEG-Apt)。使用双乳化挥发法制备包裹DNA片段的PLGA-PEG-Apt新型纳米基因药物载体,表征检测显示:制备的纳米基因载体粒径为(225.2±8.1)nm,Zeta电位约(-35.5±-3.3)mV。扫描电子显微镜下纳米颗粒形态呈圆形,表面光滑,粒径分布较均匀。纳米粒子对TFO的包封率为(25.4±3.1)%(n=3),载药量为(1.34±0.16)μg/mg。体外释放实验研究结果显示持续释放过程达23 d,且PLGA-PEG-Apt纳米粒子呈突释之后的持续缓释过程。细胞水平实验结果显示,A10适配子修饰的纳米基因载体能更多进入靶向的前列腺癌细胞株,进而发挥其抗前列腺癌增殖的作用。该研究成功制备了靶向PLGA纳米基因载体,结果满意。     

载紫杉醇星型M-PLA-TPGS纳米颗粒的合成及其用于前列腺癌治疗药物载体的研究

合成了一种甘露醇引发的星型共聚物甘露醇-聚乳酸-聚乙三醇1000维生素E琥珀酸酯(M-PLATPGS).利用纳米沉淀法制备载紫杉醇M-PLA-TPGS纳米颗粒.纳米颗粒近似球形,粒径分布较窄.对载药纳米颗粒进行粒径、表面电荷、载药量、包封率和体外药物释放的表征,结果表明,体外药物释放呈双相释放模型,M-PLA-TPGS纳米颗粒在前列腺癌PC-3细胞中的摄取水平要高于PLGA和PLA-TPGS纳米颗粒.载紫杉醇M-PLA-TPGS纳米颗粒对于前列腺癌细胞的的毒性显著高于载紫杉醇PLA-TPGS纳米颗粒和商业制剂Taxol,证明星型M-PLA-TPGS聚合物作为纳米药物载体优于线性PLGA和PLA-TPGS聚合物.     

通过可控沉积和交联制备蛋白质微胶囊

通过加入反溶剂控制牛血清白蛋白(BSA)在碳酸锰微粒表面的沉积, 形成连续薄膜后交联, 去除模板后得到了尺寸均匀和分散良好的BSA中空微胶囊. 囊壁厚度可以通过滴加乙醇控制; 囊壁的截留分子量在70000—155000之间. 由于BSA含有丰富的自由羧基, 得到的微胶囊表现出pH响应性. 这种快速简便制备微胶囊的方法也可以应用于其它蛋白质及酶, 得到的生物相容的微胶囊将在药物控制释放等领域具有潜在的应用价值.     

壳聚糖纳米微球对牛血清蛋白的包封和缓释效果研究

壳聚糖(chitosan,CS)是甲壳素脱乙酰化的产物,是由葡萄糖结构单元组成的直链多糖。CS作为一种带正电荷的天然多糖,本身具有无毒、无刺激性、无致敏性、无致突变的性质,降解产物为低分子壳寡糖和葡萄糖胺,具有良好的生物相容性和生物降解性[1-2]。CS本身具有的特性,引起了人们的     

In vitro release of protein from poly(butylcyanoacrylate) nanocapsules with an aqueous core

Factors influencing the in vitro release of bovine serum albumin (BSA) from poly(butylcyanoacrylate) (PBCA) nanocapsules, such as the pH value, BSA loading, the polymeric nanocapsule walls and protein molecular weight, were investigated in detail. The BSA release rate was affected by the degradation rate of the polymeric wall and protein loading. For low molecular weight proteins, the initial burst release was faster than that of high molecular weigh proteins and got to equilibrium quickly. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis results showed that BSA encapsulated within PBCA nanocapsules did not suffer covalent aggregation or fragmentation during the initial days of in vitro incubation. For nanocapsules prepared by interfacial polymerization in water-in-oil microemulsions, these findings were useful as a foundation for the development of nanocapsules with desired properties.     

Preparation of PLGA microspheres with different porous morphologies

Poly(D,L-lactide-co-glycolide)(PLGA) microspheres were prepared by emulsion solvent evaporation method. The influences of inner aqueous phase, organic solvent, PLGA concentration on the morphology of microspheres were studied. The results showed that addition of porogen or surfactants to the inner aqueous phase, types of organic solvents and polymer concentration affected greatly the microsphere morphology. When dichloromethane was adopted as organic solvent, microspheres with porous structure were produced. When ethyl acetate served as organic solvent, two different morphologies were obtained. One was hollow microspheres with thin porous shell under a lower PLGA concentration, another was erythrocyte-like microspheres under a higher PLGA concentration. Three types of microspheres including porous, hollow core with thin porous shell(denoted by hollow in brief) and solid structures were finally selected for in vitro drug release tests. Bovine serum albumin(BSA) was chosen as model drug and encapsulated within the microspheres. The BSA encapsulation efficiency of porous, hollow and solid microspheres was respectively 90.4%, 79.8% and 0. And the ultimate accumulative release was respectively 74.5%, 58.9% and 0. The release rate of porous microspheres was much slower than that of hollow microspheres. The experiment results indicated that microspheres with different porous structures showed great potentials in controlling drug release behavior.     

Novel alginate-poly(L-histidine) microcapsules as drug carriers: in vitro protein release and short term stability

Spherical, smooth-surfaced and mechanically stable alginate-poly(L-histidine) (PLHis) microcapsules with narrow particle size distributions were prepared by incubating calcium alginate beads in aqueous solutions of PLHis. The in vitro release characteristics, drug loading and encapsulation efficiency of the microcapsules were investigated using bovine erythrocytes hemoglobin (Hb) as a model drug. The results showed that the concentration of Ca(2+) ions had a considerable effect on the drug loading, encapsulation efficiency and in vitro release behavior of the microcapsules. When the concentration of CaCl(2) in the PLHis solution was increased from 0 to 3.0% (w/v), the drug loading and encapsulation efficiency decreased significantly from 38.0 to 4.3% and from 92.9 to 8.0%, respectively, while the total cumulative release of Hb from microcapsules in phosphate buffered saline solution (PBS, pH 6.8) decreased from 96.2 to 72.8% in 24 h. No significant protein release was observed during 70 h of incubation in hydrochloric acid solution (pH 1.2). However, under neutral conditions (PBS, pH 6.8), the Hb was completely and stably released within 24-70 h. An explosion test showed that the stability of alginate-PLHis microcapsules depended strongly on the concentration of PLHis and the calcium ions in solution. [Diagram: see text] Microscopy photo of Hb-loaded alginate-PLHis microcapsules.     

Rattle-type hollow CaWO4:Tb(3+)@SiO2 nanocapsules as carriers for drug delivery

Rattle-type hollow nanocapsules are among of the most promising candidates as drug carriers owing to their huge inner space and multifunctional material combination. In this paper, rattle-type hollow CaWO(4):Tb(3+)@SiO(2) nanocapsules with a diameter of 100-110 nm and a wall thickness around 10 nm were fabricated. The hollow silica nanospheres were used as nano-reactors and the luminescent core of CaWO(4):Tb(3+) was post-filled into the nano-reactors by a vacuum nano-casting route combined with a Pechini-type sol-gel method. Subsequently, doxorubicin hydrochloride (DOX), a model of an anti-cancer drug, is loaded into the CaWO(4):Tb(3+)@SiO(2) nanocapsules and their cell cytotoxicity, cancer cell uptake and drug release behavior are investigated in vitro. The prepared multifunctional inorganic nanocapsules show a loading capacity for DOX as high as 124 mg g(-1) and sustained-release properties. The release profile of the drug from DOX-loaded nanocapsules can last over five days. Besides, the blank CaWO(4):Tb(3+)@SiO(2) shows very low cytotoxicity against cancer cell lines (HeLa cell) while the DOX-loaded nanocapsules exhibit relatively high efficiency for killing of HeLa cells. The rapid cancer cell uptake process is observed by confocal laser scanning microscopy. The results indicate that a rattle-type hollow CaWO(4):Tb(3+)@SiO(2) nanocapsule has the potential to be used as drug carrier in therapy. Moreover, it is possible to extend the synthetic strategy in this study to other rattle-type multifunctional composites to meet various demands.     

Encapsulation of L-dopa and catechol in bovine serum albumin nanocarrier using desolvation method and their in vitro release studies

In the current study, the interaction between L-dopa and bovine serum albumin (BSA) as well as catechol and BSA is investigated separately. In order to achieve the optimum values for encapsulated efficiency (EE), the content of crosslinker/BSA, organic/aqueous phase, drug/BSA, stirring rate, and pH were closely studied taking the advantage of Taguchi method. Particle characterization was carried out using transmission electron microscopy and dynamic light scattering techniques. The most appropriate catechol and L-dopa nanoparticles in the size range of 100 nm and 65 nm, respectively, and at optimized conditions of drug/BSA = 0.1, pH = 7.4, crosslinker/BSA = 0.084, organic/aqueous phase = 4 and stirring rate 400 rpm were obtained. The most favorable EE (encapsulation efficiency) and LC (loading capacity) for L-dopa and catechol was estimated to be 88.1% and 83.6%, respectively, and the calculated LC% was achieved 93.4% and 89.7% for L-dopa and catechol, respectively. The chromatographic analyses results were also found to be in a good agreement with the obtained data for the calculated EE% and LC% values. in vitro release of loaded drugs from nanoparticles in phosphate-buffered saline (pH = 7.4, incubated at 37 ± 0.5°C under stirring rate of 100 rpm) showed the release of 78% catechol and 89% L-dopa during 480 min and 510 min, respectively.     

Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables

This study aimed to prepare solid lipid nanoparticles (SLNs) of a hydrophobic drug, tretinoin, by emulsification-ultrasonication method. Solubility of tretinoin in the solid lipids was examined. Effects of process variables were investigated on particle size, polydispersity index (PI), zeta potential (ZP), drug encapsulation efficiency (EE), and drug loading (L) of the SLNs. Shape and surface morphology of the SLNs were investigated by cryogenic field emission scanning electron microscopy (cryo-FESEM). Complete encapsulation of drug in the nanoparticles was checked by cross-polarized light microscopy and differential scanning calorimetry (DSC). Crystallinity of the formulation was analyzed by DSC and powder X-ray diffraction (PXRD). In addition, drug release and stability studies were also performed. The results indicated that 10mg tretinoin was soluble in 0.45±0.07 g Precirol? ATO5 and 0.36±0.06 g Compritol? 888ATO, respectively. Process variables exhibited significant influence in producing SLNs. SLNs with <120 nm size, <0.2 PI, >I30I mV ZP, >75% EE, and ～0.8% L can be produced following the appropriate formulation conditions. Cryo-FESEM study showed spherical particles with smooth surface. Cross-polarized light microscopy study revealed that drug crystals in the external aqueous phase were absent when the SLNs were prepared at ≤0.05% drug concentration. DSC and PXRD studies indicated complete drug encapsulation within the nanoparticle matrix as amorphous form. The drug release study demonstrated sustained/prolonged drug release from the SLNs. Furthermore, tretinoin-loaded SLNs were stable for 3 months at 4°C. Hence, the developed SLNs can be used as drug carrier for sustained/prolonged drug release and/or to improve oral absorption/bioavailability.     

Performance of biodegradable microcapsules of poly(butylene succinate), poly(butylene succinate-co-adipate) and poly(butylene terephthalate-co-adipate) as drug encapsulation systems

Poly(butylene succinate) (PBSu), poly(butylene succinate-co-adipate) (PBSA) and poly(butylene terephthalate-co-adipate) (PBTA) microcapsules were prepared by the double emulsion/solvent evaporation method. The effect of polymer and poly(vinyl alcohol) (PVA) concentration on the microcapsule morphologies, drug encapsulation efficiency (EE) and drug loading (DL) of bovine serum albumin (BSA) and all-trans retinoic acid (atRA) were all investigated. As a result, the sizes of PBSu, PBSA and PBTA microcapsules were increased significantly by varying polymer concentrations from 6 to 9%. atRA was encapsulated into the microcapsules with an high level of approximately 95% EE. The highest EE and DL of BSA were observed at 1% polymer concentration in values of 60 and 37%, respectively. 4% PVA was found as the optimum concentration and resulted in 75% EE and 14% DL of BSA. The BSA release from the capsules of PBSA was the longest, with 10% release in the first day and a steady release of 17% until the end of day 28. The release of atRA from PBSu microcapsules showed a zero-order profile for 2 weeks, keeping a steady release rate during 4 weeks with a 9% cumulative release. Similarly, the PBSA microcapsules showed a prolonged and a steady release of atRA during 6 weeks with 12% release. In the case of PBTA microcapsules, after a burst release of 10% in the first day, showed a parabolic release profile of atRA during 42 days, releasing 36% of atRA.     

Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsification method and its release in vitro

Uniform-sized biodegradable PLA/PLGA microcapsules loading recombinant human insulin (rhI) were successfully prepared by combining a Shirasu Porous Glass (SPG) membrane emulsification technique and a double emulsion-evaporation method. An aqueous phase containing rhI was used as the inner water phase (w1), and PLA/PLGA and Arlacel 83 were dissolved in a mixture solvent of dichloromethane (DCM) and toluene, which was used as the oil phase (o). These two solutions were emulsified by a homogenizer to form a w1/o primary emulsion. The primary emulsion was permeated through the uniform pores of a SPG membrane into an outer water phase by the pressure of nitrogen gas to form the uniform w1/o/w2 droplets. The solid polymer microcapsules were obtained by simply evaporating solvent from droplets. Various factors of the preparation process influencing the drug encapsulation efficiency and the drug cumulative release were investigated systemically. The results indicated that the drug encapsulation efficiency and the cumulative release were affected by the PLA/PLGA ratio, NaCl concentration in outer water phase, the inner water phase volume, rhI-loading amount, pH-value in outer water phase and the size of microcapsules. By optimizing the preparation process, the drug encapsulation efficiency was high up to 91.82%. The unique advantage of preparing drug-loaded microcapsules by membrane emulsification technique is that the size of microcapsules can be controlled accurately, and thus the drug cumulative release profile can be adjusted just by changing the size of microcapsules. Moreover, much higher encapsulation efficiency can be obtained when compared with the conventional mechanical stirring method.     

Ionically crosslinked alginate/carboxymethyl chitin beads for oral delivery of protein drugs

Complex beads composed of alginate and carboxymethyl chitin (CMCT) were prepared by dropping aqueous alginate-CMCT into an iron(III) solution. The structure and morphology of the beads were characterized by IR spectroscopy and scanning electron microscopy (SEM). IR confirmed electrostatic interactions between iron(III) and the carboxyl groups of alginate as well as CMCT, and the binding model was suggested as a three-dimensional structure. SEM revealed that CMCT had a porous morphology while alginate and their complex beads had a core-layer structure. The swelling behavior, encapsulation efficiency, and release behavior of bovine serum albumin (BSA) from the beads at different pHs were investigated. The BSA encapsulation efficiency was fairly high (>90%). It was found that CMCT disintegrated at pH 1.2 and alginate eroded at pH 7.4 while the complex beads could effectively retain BSA in acid (>85%) and reduce the BSA release at pH 7.4. The results suggested that the iron(III)-alginate-CMCT bead could be a suitable polymeric carrier for site-specific protein drug delivery in the intestine.